Drug-induced reduction in estimated glomerular filtration rate in patients with ALK-positive non-small cell lung cancer treated with the ALK inhibitor crizotinib

Cancer

Volumn 120, Issue 5, 2014, Pages 664-674

  Brosnan, Evelyn M ^a   Weickhardt, Andrew J ^a   Lu, Xian ^b   Maxon, Delee A ^a   Barón, Anna E ^b   Chonchol, Michel ^c   Camidge, D Ross ^a  

^a UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^b Global Health and Health Disparities   (United States)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

anaplastic lymphoma kinase (ALK) gene rearrangements; crizotinib; glomerular filtration rate (GFR); kidney injury; non small cell lung cancer; renal function

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CREATININE; CRIZOTINIB; NITROGEN; UREA;

ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFECT; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTRANSAMINASEMIA; KIDNEY FAILURE; LUNG NON SMALL CELL CANCER; MALE; MIDDLE AGED; NEUTROPENIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR CELL DESTRUCTION; UREA NITROGEN BLOOD LEVEL; YOUNG ADULT;

ANAPLASTIC LYMPHOMA KINASE (ALK) GENE REARRANGEMENTS; CRIZOTINIB; GLOMERULAR FILTRATION RATE (GFR); KIDNEY INJURY; NON-SMALL CELL LUNG CANCER; RENAL FUNCTION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; ELECTRONIC HEALTH RECORDS; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84896718907     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28478     Document Type: Article

References (28)

1. American Cancer Society. Cancer Facts & Figures 2013. cancer.org/research/cancerfactsfigures/index. Accessed March 1, 2013.
2. Kwak E, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010; 363: 1693-1703.
3. Shaw AT, et al. Phase III study of crizotinib versus pemetrexed or docetaxel chemotherapy in patients with advanced ALK-positive non-small cell lung cancer (NSCLC) (PROFILE 1007). Ann Oncol. 2012: 23 (suppl 9):LBA1-PR.
4. Camidge DR, Bang YJ, Kwak E, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol. 2012; 13: 1011-1019.
5. National Comprehensive Cancer Network. NCCN Flash Update: NCCN Guidelines Updated. nccn.org/about/news/ebulletin/2011-11-14/guidelines-compendium.asp. Accessed January 18, 2013.
6. Weickhardt AJ, Rothman MS, Salian-Mehta S, et al. Rapid-onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer. Cancer. 2012; 118: 5302-5309.
7. Ou SH, Azada M, Dy J, Stiber JA,. Asymptomatic profound sinus bradycardia (heart rate ≤ 45) in non-small cell lung cancer patients treated with crizotinib. J Thorac Oncol. 2011; 6: 2135-2137.
8. Tamiya A, Okamoto I, Miyazaki M, Shimizu S, Kitaichi M, Nakagawa K,. Severe acute interstitial lung disease after crizotinib therapy in a patient with EML4-ALK-positive non-small-cell lung cancer. J Clin Oncol. 2013; 31: e15-e17.
9. US Food and Drug Administration. Approval History XALKORI, NDA no. 202570, http://labeling.pfizer.com/showlabeling.aspx?id=676. Accessed November 15, 2013.
10. Murata K, Baumann NA, Saenger AK, Larson TS, Rule AD, Lieske JC,. Relative performance of the MDRD and CKD-EPI equations for estimating glomerular filtration rate among patients with varied clinical presentations. Clin J Am Soc Nephrol. 2011; 6: 1963-1972.
11. Earley A, Miskulin D, Lamb EJ, Levey AS, Uhlig K,. Estimating equations for glomerular filtration rate in the era of creatinine standardization: a systematic review. Ann Intern Med. 2012; 156: 785-795.
12. Laird NM, Ware JH,. Random-effects models for longitudinal data. Biometrics. 1982; 38: 963-974.
13. Christensen JG, Zou HY, Arango ME, et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther. 2007; 6 (12 pt 1): 3314-3322.
14. Zou HY, Li Q, Lee JH, et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res. 2007; 67: 4408-4417.
15. Camidge DR, Doebele RC,. Treating ALK-positive lung cancer-early successes and future challenges. Nat Rev Clin Oncol. 2012; 9: 268-277.
16. Weickhardt AJ, Scheier B, Burke JM, et al. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol. 2012; 7: 1807-1814.
17. Al-Kali A, Farooq S, Tfayli A,. Tumor lysis syndrome after starting treatment with Gleevec in a patient with chronic myelogenous leukemia. J Clin Pharm Ther. 2009; 34: 607-610.
18. Wilson FP, Berns JS,. Onco-nephrology: tumor lysis syndrome. Clin J Am Soc Nephrol. 2012; 7: 1730-1739.
19. Ciarimboli G, Lancaster CS, Schlatter E, et al. Proximal tubular secretion of creatinine by organic cation transporter OCT2 in cancer patients. Clin Cancer Res. 2012; 18: 1101-1108.
20. Breyer MD, Qi Z,. Better nephrology for mice-and man. Kidney Int. 2010; 77: 487-489.
21. Urakami Y, Kimura N, Okuda M, Inui K,. Creatinine transport by basolateral organic cation transporter hOCT2 in the human kidney. Pharm Res. 2004; 21: 976-981.
22. Burgess E, Blair A, Krichman K, Cutler RE,. Inhibition of renal creatinine secretion by cimetidine in humans. Ren Physiol. 1982; 5: 27-30.
23. van Acker BA, Koomen GC, Koopman MG, de Waart DR, Arisz L,. Creatinine clearance during cimetidine administration for measurement of glomerular filtration rate. Lancet. 1992; 340: 1326-1329.
24. Kastrup J, Petersen P, Bartram R, Hansen JM,. The effect of trimethoprim on serum creatinine. Br J Urol. 1985; 57: 265-268.
25. Myre SA, McCann J, First MR, Cluxton RJ Jr,. Effect of trimethoprim on serum creatinine in healthy and chronic renal failure volunteers. Ther Drug Monit. 1987; 9: 161-165.
26. Naderer O, Nafziger AN, Bertino JS Jr,. Effects of moderate-dose versus high-dose trimethoprim on serum creatinine and creatinine clearance and adverse reactions. Antimicrob Agents Chemother. 1997; 41: 2466-2470.
27. Opravil M, Keusch G, Luthy R,. Pyrimethamine inhibits renal secretion of creatinine. Antimicrob Agents Chemother. 1993; 37: 1056-1060.
28. Zaltzman JS, Whiteside C, Cattran DC, Lopez FM, Logan AG,. Accurate measurement of impaired glomerular filtration using single-dose oral cimetidine. Am J Kidney Dis. 1996; 27: 504-511.